Joseph Tauber

TL;DR: It became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size.

TL;DR: The goals of the subcommittee were to review the current practice and published evidence of medical and surgical treatment options for meibomian gland dysfunction and to identify areas with conflicting, or lack of, evidence, observations, concepts, or even mechanisms where further research is required.

TL;DR: In this article, the authors investigated the efficacy, safety, formulation tolerability, and optimal dosing of a novel cyclosporin A oil-in-water emulsion formulation for the treatment of moderate-to-severe dry eye disease.

TL;DR: Therapy of chronic dry eye disease with cyclosporine 0.1% ophthalmic emulsion for 1 to 3 years was safe, well tolerated, and not associated with systemic side effects.

TL;DR: Scleritis is associated more often with ocular complications than episcleritis, and necrotizing sclerococcus is the type of scleritis most often associated with ophthalmic complications and disease association and associated infectious disease.